Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Hoffmann-La Roche AG announced a collaboration and licensing agreement with Zealand Pharma to develop and co-commercialize petrelintide. Petrlintide is Zealand’s long-acting amylin analog drug.

Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis-based diagnostics unit. The Swiss pharmaceutical and diagnostics giant ...

Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid ...

Roche acquired rights to petrelintide, an obesity therapy from Denmark's Zealand Pharma in March. This therapy is currently undergoing mid-stage clinical trials. Roche's obesity pipeline also ...

Roche acquired rights to petrelintide, an obesity therapy from Denmark's Zealand Pharma (ZELA.CO), opens new tab in March. This therapy is currently undergoing mid-stage clinical trials.